Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Glucagon-like peptide-1, glucose homeostasis and diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Sphingosine-1-Phosphate Signaling in Inflammatory Bowel Disease

    Research output: Contribution to journalReviewResearchpeer-review

  2. Exercise-Dependent Regulation of NK Cells in Cancer Protection

    Research output: Contribution to journalReviewResearchpeer-review

  3. Endothelial Glycocalyx: Shedding Light on Malaria Pathogenesis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Glycemic Control and Variability of Diabetes Secondary to Total Pancreatectomy Assessed by Continuous Glucose Monitoring

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The renal extraction and the natriuretic action of GLP-1 in humans depend on interaction with the GLP-1 receptor

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Fractionated free fatty acids and their relation to diabetes status after Roux-en-Y gastric bypass: A cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Incretins, enhancers of insulin secretion, are essential for glucose tolerance, and a reduction in their function might contribute to poor beta-cell function in patients with type-2 diabetes mellitus. However, at supraphysiological doses, the incretin glucagon-like peptide-1 (GLP-1) protects pancreatic beta cells, and inhibits glucagon secretion, gastric emptying and food intake, leading to weight loss. GLP-1 mimetics, which are stable-peptide-based activators of the GLP-1 receptor, and incretin enhancers, which inhibit the incretin-degrading enzyme dipeptidyl peptidase-4, have emerged as therapies for type-2 diabetes and have recently reached the market. The pathophysiological basis the clinical use of these therapeutics is reviewed here.
Original languageEnglish
JournalTrends in Molecular Medicine
Volume14
Issue number4
Pages (from-to)161-8
Number of pages8
ISSN1471-4914
DOIs
Publication statusPublished - 1 Apr 2008

ID: 32267430